A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.
Tumor microenvironment (TME) has been regarded as a critical regulating environment for immune response and tumor growth in recent years. Similar to the interaction between seeds and soil, TME ...
Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune-mediated destruction of pancreatic B cells. While autoreactive T cells are key ...
The announcement is anchored by a study published in Biomacromolecules (American Chemical Society, 2026), conducted by MindWalk in a grant-funded collaboration with Eindhoven University of Technology ...
Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...
UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results